A spokesman for the European Commission, which is due to decide on the deal by Nov. 23, declined to comment. Abbott, which also makes prescription drugs and diagnostics, had no immediate comment. St. Jude officials could not be reached for comment.
More:
Exclusive: EU regulators seen clearing $25 billion Abbott, St Jude deal: source
